Dihydroxyphenyl Neurotransmitter Compounds, Compositions And Methods

1 . A compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 -R 2 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C 1 -C 6 -alkyl, and C 5 -C 6 -cycloalkyl, wherein said C 1 -C 6 -alkyl and C 5 -C 6 -cycloalkyl may be optionally substituted with deuterium;

R 3 -R 8 are independently selected from the group consisting of hydrogen and deuterium;

R 9 -R 11 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C 1 -C 6 -alkyl, and C 5 -C 6 -cycloalkyl, wherein said C 1 -C 6 -alkyl and C 5 -C 6 -cycloalkyl may be optionally substituted with deuterium; and

at least one of R 3 -R 6 and R 8 is deuterium.

2 . The compound as recited in claim 1 , wherein said compound is not enriched by carbon-13.

3 . The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of:

4 . The compound as recited in claim 3 , wherein each position represented as D has deuterium enrichment of no less than about 10%, no less than about 50%, no less than about 90%, or no less than about 98%.

5 . The compound as recited in claim 3 , wherein said compound has a structural formula selected from the group consisting of:

6 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 -R 2 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C 1 -C 6 -alkyl, and C 5 -C 6 -cycloalkyl, wherein said C 1 -C 6 -alkyl and C 5 -C 6 -cycloalkyl may be optionally substituted with deuterium;

R 3 -R 8 are independently selected from the group consisting of hydrogen and deuterium;

R 9 -R 11 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C 1 -C 6 -alkyl, and C 5 -C 6 -cycloalkyl, wherein said C 1 -C 6 -alkyl and C 5 -C 6 -cycloalkyl may be optionally substituted with deuterium; and

at least one of R 3 -R 6 and R 8 is deuterium.

7 . A method of treating a neurotransmitter-mediated disorder comprising administering a therapeutically effective amount of a compound of structural Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 -R 2 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C 1 -C 6 -alkyl, and C 5 -C 6 -cycloalkyl, wherein said C 1 -C 6 -alkyl and C 5 -C 6 -cycloalkyl may be optionally substituted with deuterium;

R 3 -R 8 are independently selected from the group consisting of hydrogen and deuterium;

R 9 -R 11 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C 1 -C 6 -alkyl, and C 5 -C 6 -cycloalkyl, wherein said C 1 -C 6 -alkyl and C 5 -C 6 -cycloalkyl may be optionally substituted with deuterium; and

at least one of R 3 -R 6 and R 8 is deuterium.

8 . The method as recited in claim 7 , wherein said disorder is selected from the group consisting of hypotension, orthostatic hypotension, neurogenic orthostatic hypotension, symptomatic neurogenic orthostatic hypotension, neurogenic orthostatic hypotension associated with multiple system atrophy (MSA), orthostatic hypotension associated with Shy-Drager syndrome, neurogenic orthostatic hypotension associated with familial amyloid polyneuropathy (FAP), neurogenic orthostatic hypotension associated with pure autonomic failure (PAF), idiopathic orthostatic hypotension, asympathicotonic hypotension, neurogenic orthostatic hypotension associated with Parkinson's disease, intradialytic hypotension (IDH), hemodialysis-induced hypotension, hypotension associated with fibromyalgia syndrome (FMS), hypotension in spinal cord injury, hypotension associated with chronic fatigue syndrome (CFS), frozen gait, akinesia, and dysarthria in Parkinson's disease, Lewy body dementia, rapid eye movement (REM) behavior disorder, chronic heart failure, stress-related disorders, motor or speech disturbances, chronic pain, stroke, cerebral ischemia, nasal congestion, mood disorders, sleep disorders, narcolepsy, insomnia, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), anosmia, hyposmia, mild cognitive impairment (MCI), Down syndrome, Alzheimer's disease, postural reflex abnormality caused by Parkinson's disease, autoimmune autonomic failure, familial dysautonomia, diabetic autonomic neuropathy, amyloidosis in the setting of multiple myeloma, Parkinson's disease, proprandial hypotension, dopamine beta-hydroxylase deficiency, pain, progressive supranuclear palsy, Menkes disease, familial dysautonomia (Riley-Day Syndrome), PD-related dysautonomia (autonomic dysfunction), orthostatic intolerance in adolescents, neurocardiogenic syncope (vasovagal), postural orthostatic tachycardia syndrome (POTS), fibromyalgia, allodynia, hyperalgesia, fatigue, sleep disturbance, depression, chronic orthostatic intolerance, pediatric developmental disorders, genetic diseases involving decreased norepinephrine synthesis or effects, multi-system disorders of regulation, pain, neurodegenerative diseases, cognitive dysfunction, olfactory disorders, neuroendocrine disorders, and autoimmune disorders.

9 . The method as recited in claim 7 , wherein said disorder is selected from the group consisting of orthostatic hypotension, neurogenic orthostatic hypotension associated with multiple system atrophy (MSA), orthostatic hypotension associated with Shy-Drager syndrome, neurogenic orthostatic hypotension associated with familial amyloid polyneuropathy (FAP), neurogenic orthostatic hypotension associated with pure autonomic failure (PAF), idiopathic orthostatic hypotension, asympathicotonic hypotension, neurogenic orthostatic hypotension associated with Parkinson's disease, intradialytic hypotension (IDH), hemodialysis-induced hypotension, hypotension associated with fibromyalgia syndrome (FMS), hypotension in spinal cord injury, and hypotension associated with chronic fatigue syndrome (CFS).

10 . The method as recited in claim 7 , wherein said disorder is orthostatic hypotension.

11 . The method as recited in claim 7 , wherein said disorder is selected from the group consisting of dopamine-beta-hydroxylase deficiency, Menkes disease, lack of vitamin C, Lewy body diseases, Parkinson's disease, Lewy body dementia, pure autonomic failure, familial dysautonomia, status-post bilateral endoscopic thoracic sympathectomy, orthostatic intolerance, and orthostatic hypotension.

12 . The method as recited in claim 7 , further comprising administering an additional therapeutic agent.

13 . The method as recited in claim 12 , wherein said additional therapeutic agent is selected from the group consisting of sympathomimetic agents, S-alkylisothiouronium derivatives, glucocorticoids, analeptics, psychotropics, positive inotropic agents, antihypotensive agents, L-aromatic-amino acid decarboxylase inhibitors, catechol-O-methyltransferase inhibitors, monoamine oxidase inhibitors, and 5-HT 2A inverse agonist.

14 . The method as recited claim 7 , wherein each position in said compound represented as D has deuterium enrichment of no less than about 10%, no less than about 50%, no less than about 90%, or no less than about 98%.

15 . The method as recited claim 7 , wherein said compound has a structural formula that is: